Developed From Core Technology
Humacyte, a privately held company, is primarily focused on developing investigational products for vascular disease and for replacement of anatomical conduits. The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based investigational tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. Incorporated in 2005, Humacyte licensed technology from MIT and Duke University. Since then, Humacyte has made considerable progress in the development and pre-clinical testing of our investigational biologic vascular grafts.